DK201100050U1 - Rasagilinformulering med forsinket frigivelse - Google Patents

Rasagilinformulering med forsinket frigivelse

Info

Publication number: DK201100050U1
Authority: DK; Denmark
Prior art keywords: delayed release; release rasagiline; formulation; rasagiline formulation; delayed
Prior art date: 2009-01-23

Application number

DKBA201100050U

Other languages

English (en)

Inventor

Safadi Muhammad

Licht Daniella

Cohen Rachel

Frenkel Anton

Zholkovsky Marina

Koltai Tamas

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-23

Filing date

2011-03-11

Publication date

2011-07-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42354337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK201100050(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-03-11 Application filed by Teva Pharma filed Critical Teva Pharma

2011-07-08 Publication of DK201100050U1 publication Critical patent/DK201100050U1/da

2014-10-24 Application granted granted Critical

2014-10-24 Publication of DK201100050U4 publication Critical patent/DK201100050U4/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DKBA201100050U 2009-01-23 2011-03-11 Rasagilinformulering med forsinket frigivelse DK201100050U4 (da)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US20583309P	2009-01-23	2009-01-23
US12/455,976 US8080584B2 (en)	2009-01-23	2009-06-09	Delayed release rasagiline citrate formulation
US12/456,031 US20100189788A1 (en)	2009-01-23	2009-06-09	Delayed release rasagiline base formulation
US12/456,001 US20100189791A1 (en)	2009-01-23	2009-06-09	Delayed release rasagiline malate formulation
US12/456,029 US20100189790A1 (en)	2009-01-23	2009-06-09	Delayed release rasagiline formulation
US12/689,044 US7855233B2 (en)	2009-01-23	2010-01-18	Citrate salt of Rasagiline
EP10186379A EP2308477B1 (en)	2009-01-23	2010-01-22	Delayed release rasagiline formulation

Publications (2)

Publication Number	Publication Date
DK201100050U1 true DK201100050U1 (da)	2011-07-08
DK201100050U4 DK201100050U4 (da)	2014-10-24

Family

ID=42354337

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK10186379.3T DK2308477T3 (da)	2009-01-23	2010-01-22	Rasagilinformulering med forsinket frisætning
DK10166534.7T DK2246321T3 (da)	2009-01-23	2010-01-22	Rasagilinformulering med forsinket frisætning
DKBA201100050U DK201100050U4 (da)	2009-01-23	2011-03-11	Rasagilinformulering med forsinket frigivelse

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
DK10186379.3T DK2308477T3 (da)	2009-01-23	2010-01-22	Rasagilinformulering med forsinket frisætning
DK10166534.7T DK2246321T3 (da)	2009-01-23	2010-01-22	Rasagilinformulering med forsinket frisætning

Country Status (21)

Country	Link
US (9)	US20100189788A1 (da)
EP (3)	EP2381767B1 (da)
JP (2)	JP5774495B2 (da)
CN (1)	CN102333442B (da)
AR (1)	AR075148A1 (da)
AT (3)	ATE556703T1 (da)
AU (1)	AU2010206970B2 (da)
CA (3)	CA2799515A1 (da)
CY (2)	CY1112486T1 (da)
CZ (1)	CZ22819U1 (da)
DE (1)	DE202010017129U1 (da)
DK (3)	DK2308477T3 (da)
EA (1)	EA029262B1 (da)
ES (3)	ES2564317T3 (da)
HR (2)	HRP20110745T1 (da)
IL (1)	IL214220A (da)
PL (2)	PL2308477T3 (da)
PT (2)	PT2308477E (da)
RS (2)	RS52421B (da)
SI (2)	SI2308477T1 (da)
WO (1)	WO2010085354A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2574925A1 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) *	2004-11-24	2012-01-11	Teva Pharmaceutical Industries Ltd.	Composiciones de rasagilina de disgregación oral.
ES2551481T3 (es) *	2006-02-21	2015-11-19	Teva Pharmaceutical Industries, Ltd.	Uso de rasagilina para el tratamiento de atrofia multisistémica
NZ571591A (en)	2006-04-03	2011-09-30	Teva Pharma	Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
HRP20110980T1 (hr) *	2006-12-14	2012-02-29	Teva Pharmaceutical Industries Ltd.	Kristalna kruta rasagilinska baza
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) *	2007-09-05	2009-03-05	Laurence Oron	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) *	2008-01-11	2012-08-31	Teva Pharma	Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
WO2009151594A1 (en) *	2008-06-10	2009-12-17	Teva Pharmaceutical Industries, Ltd.	Rasagiline soft gelatin capsules
CA2727022A1 (en) *	2008-06-13	2009-12-17	Teva Pharmaceutical Industries Ltd.	Rasagiline for parkinson's disease modification
EP2299993A4 (en) *	2008-06-19	2014-08-20	Teva Pharma	PROCESS FOR PURIFYING THE BASE OF RASAGILINE
JP2011524907A (ja) *	2008-06-19	2011-09-08	テバファーマシューティカルインダストリーズリミティド	固体ラサギリン塩基を調製および乾燥する方法
US20100189788A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline base formulation
ITPR20090047A1 (it) *	2009-06-16	2010-12-17	Agricola Cerasaro S S Soc	Procedimento per la produzione di un trito o crema di aglio e trito o crema di aglio cosi' ottenuta
DK2451771T3 (da)	2009-07-09	2014-09-08	Ratiopharm Gmbh	Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2485722A1 (en) *	2009-10-09	2012-08-15	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
WO2011087791A1 (en) *	2009-12-22	2011-07-21	Teva Pharmaceutical Industries Ltd.	3-keto-n-propargyl-1-aminoindan
CA2806740A1 (en)	2010-07-27	2012-02-02	Teva Pharmaceutical Industries Ltd.	Use of rasagiline for the treatment of olfactory dysfunction
US8691872B2 (en)	2010-07-27	2014-04-08	Teva Pharmaceutical Industries Ltd.	Dispersions of rasagiline citrate
JP2014503480A (ja) *	2010-10-26	2014-02-13	テバファーマシューティカルインダストリーズリミティド	ジュウテリウムリッチなラサギリン
HU231054B1 (hu) *	2010-11-18	2020-04-28	Egis Gyógyszergyár Nyrt.	Gyógyászati készítmény előállítására alkalmazható új sók
ES2662373T3 (es)	2011-01-19	2018-04-06	Pathologica, Llc.	Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG
JP2014534196A (ja)	2011-10-10	2014-12-18	テバファーマシューティカルインダストリーズリミティド	Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン
EP2766004A4 (en) *	2011-10-10	2015-04-22	Teva Pharma	R (+) - N-methyl-propargyl-aminoindan
EP2766007A4 (en) *	2011-10-10	2015-03-25	Teva Pharma	RASAGILINE CITRAMIDE
EP2827848B1 (en)	2012-03-21	2016-04-27	Synthon BV	Stabilized pharmaceutical compositions comprising rasagiline salts
BR112015003451A2 (pt)	2012-08-17	2017-07-04	Teva Pharma	formulação parentérica de rasagilina
JP2014050039A (ja) *	2012-09-03	2014-03-17	Sony Corp	画像処理装置、画像処理方法及びコンピュータプログラム
CN109432073A (zh)	2013-01-08	2019-03-08	帕萨罗杰卡有限公司	Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
JP6173098B2 (ja)	2013-07-30	2017-08-02	キヤノン株式会社	光学機器
JP5897196B1 (ja)	2015-10-05	2016-03-30	大同化成工業株式会社	糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
CN107049985B (zh) *	2017-06-07	2020-06-19	广州帝奇医药技术有限公司	一种抗帕金森病药物的长效缓释制剂及其制备方法
CN109028765A (zh) *	2018-07-02	2018-12-18	无锡富泽药业有限公司	一种盐酸替罗非班的干燥方法
CN109832262A (zh) *	2019-01-25	2019-06-04	袁隆平农业高科技股份有限公司	活体植物保存方法
CN114469902B (zh) *	2020-10-23	2024-10-29	上海上药中西制药有限公司	雷沙吉兰或其药用盐舌下膜剂及其制备方法、应用
CN115400090A (zh) *	2022-10-09	2022-11-29	北京新领先医药科技发展有限公司	一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US761917A (en) *	1903-02-11	1904-06-07	Alphonse King	Telegraph-transmitter.
US5744500A (en) *	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) *	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) *	1991-10-16	2001-11-25	Teva Pharma	Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en)	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) *	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) *	1996-06-28	1997-09-02	Jame Fine Chemicals, Inc.	Process for preparing antihistamine tannates
IL118836A (en) *	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
JP4222632B2 (ja) *	1996-12-18	2009-02-12	テバ・ファーマシューティカル・インダストリーズ・リミテッド	アミノインダン誘導体
AU6417198A (en)	1997-03-13	1998-09-29	Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency	Cytoprotective agents comprising monoamine oxidase inhibitors
US6548706B2 (en) *	1999-12-23	2003-04-15	Aerojet Fine Chemicals Llc	Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
DE10041478A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
US20070197484A1 (en) *	2001-05-03	2007-08-23	Ching Song	Method of treating disorder related to high cholesterol concentration
UA73421C2 (en)	2001-05-14	2005-07-15	Pfizer Prod Inc	Cytrate salt 5,8,14-triazatetracyclo[10.3.1.02,11.04,9] hexadeca-2(11),3,5,7,9-pentaene and a pharmaceutical composition based thereon
GT200200234A (es)	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
CN100358878C (zh)	2001-12-07	2008-01-02	辉瑞产品公司	治疗化合物的柠檬酸盐及其药物组合物
US7118765B2 (en)	2001-12-17	2006-10-10	Spi Pharma, Inc.	Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
PT1567152E (pt) *	2002-11-15	2013-10-03	Teva Pharma	Uso de rasagilina com riluzol para tratar a esclerose lateral amiotrófica
AR044007A1 (es)	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
US20060177507A1 (en) *	2003-05-22	2006-08-10	Joaquina Faour	Controlled release device containing lercanidipine
PE20051096A1 (es)	2004-02-04	2006-01-23	Novartis Ag	Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
MXPA06009991A (es) *	2004-03-03	2007-04-10	Teva Pharma	Una composicion farmaceutica estable que comprende un farmaco labil acido.
US7145005B2 (en)	2004-05-12	2006-12-05	Abbott Laboratories	2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
BRPI0513598A (pt) *	2004-07-26	2008-05-13	Teva Pharma	formas de dosagem em comprimidos revestidos de liberação entérica
CA2574925A1 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical dosage forms including rasagiline
US20060069060A1 (en)	2004-09-27	2006-03-30	Sanjeev Redkar	Salts of decitabine
NZ555470A (en)	2004-11-24	2011-02-25	Teva Pharma	Rasagiline orally disintegrating compositions
ES2371883T3 (es) *	2004-11-24	2012-01-11	Teva Pharmaceutical Industries Ltd.	Composiciones de rasagilina de disgregación oral.
ES2420404T3 (es) *	2005-02-17	2013-08-23	Teva Pharmaceutical Industries Ltd.	Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
KR20170023211A (ko) *	2005-02-23	2017-03-02	테바 파마슈티컬 인더스트리즈 리미티드	함량 균일성이 개선된 라사길린 제형
US8349951B2 (en)	2005-05-31	2013-01-08	Prc Desoto International, Inc.	Polythioether polymers and curable compositions containing them
US20070078172A1 (en) *	2005-06-16	2007-04-05	Jenrin Discovery	Mao-b inhibitors useful for treating obesity
GB0514593D0 (en)	2005-07-15	2005-08-24	Davy Process Techn Ltd	Process
DK1928858T3 (da)	2005-09-19	2009-10-26	Pfizer Prod Inc	Faste saltformer af et pyrrolsubstitueret 2-indolinon
FR2891459B1 (fr) *	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CN101622225B (zh) *	2005-11-17	2015-04-15	泰华制药工业有限公司	炔丙基氨基茚分离方法
HUP0501084A2 (en)	2005-11-23	2008-05-28	Richter Gedeon Nyrt	New pharmaceutical compositions of high effectivity
US7572834B1 (en) *	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
SA07280004B1 (ar)	2006-02-02	2011-10-29	استرازينيكا ايه بي	ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
ES2551481T3 (es) *	2006-02-21	2015-11-19	Teva Pharmaceutical Industries, Ltd.	Uso de rasagilina para el tratamiento de atrofia multisistémica
JP2009528999A (ja)	2006-02-21	2009-08-13	アンプラファーマシューティカルズインコーポレイテッド	Ｃｂ１アンタゴニストおよび逆アゴニスト
CN101032474B (zh) *	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
NZ571591A (en) *	2006-04-03	2011-09-30	Teva Pharma	Use of rasagiline for the treatment of restless legs syndrome
WO2008010768A1 (en)	2006-07-17	2008-01-24	Cereuscience Ab	Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
CN1911211B (zh) *	2006-08-25	2010-04-14	重庆医药工业研究院有限责任公司	雷沙吉兰口服固体制剂
CN100542524C (zh) *	2006-09-29	2009-09-23	北京德众万全药物技术开发有限公司	一种含有雷沙吉兰的药用组合物
AR063983A1 (es)	2006-11-28	2009-03-04	Wyeth Corp	Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada
HRP20110980T1 (hr)	2006-12-14	2012-02-29	Teva Pharmaceutical Industries Ltd.	Kristalna kruta rasagilinska baza
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008076315A1 (en)	2006-12-14	2008-06-26	Teva Pharmaceutical Industries, Ltd.	Tannate salt of rasagiline
US7949403B2 (en) *	2007-02-27	2011-05-24	Accelerated Care Plus Corp.	Electrical stimulation device and method for the treatment of neurological disorders
JP2010524844A (ja)	2007-04-26	2010-07-22	エーザイ・アール・アンド・ディー・マネジメント株式会社	認知症のためのシンナミド化合物
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP5577012B2 (ja)	2007-05-03	2014-08-20	株式会社カネカ	多層基板およびその製造方法
US20090062400A1 (en) *	2007-09-05	2009-03-05	Laurence Oron	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ585752A (en)	2007-12-24	2011-11-25	Cipla Ltd	Process for the synthesis of propargylated aminoindan derivatives
NZ586025A (en) *	2008-01-11	2012-08-31	Teva Pharma	Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
US20090247537A1 (en) *	2008-03-25	2009-10-01	William Dale Overfield	Methods for preventing or treating bruxism using dopaminergic agents
EP2271612B1 (en)	2008-03-31	2016-08-10	Actavis Group PTC EHF	Rasagiline mesylate particles and process for the preparation thereof
WO2009151594A1 (en) *	2008-06-10	2009-12-17	Teva Pharmaceutical Industries, Ltd.	Rasagiline soft gelatin capsules
CA2727022A1 (en) *	2008-06-13	2009-12-17	Teva Pharmaceutical Industries Ltd.	Rasagiline for parkinson's disease modification
JP2011524907A (ja) *	2008-06-19	2011-09-08	テバファーマシューティカルインダストリーズリミティド	固体ラサギリン塩基を調製および乾燥する方法
EP2299993A4 (en) *	2008-06-19	2014-08-20	Teva Pharma	PROCESS FOR PURIFYING THE BASE OF RASAGILINE
CN101606923B (zh)	2008-06-20	2013-01-09	重庆医药工业研究院有限责任公司	一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
EA201170181A1 (ru)	2008-07-11	2011-08-30	Синтон Бв	Полиморфные формы разагилина гидрохлорида
WO2010007181A2 (en)	2008-07-18	2010-01-21	Medichem, S.A.	New salt forms of an aminoindan derivative
US20100029987A1 (en)	2008-07-29	2010-02-04	Dipharma Francis S.R.I.	Crystalline Form of Rasagiline and Process for the Preparation Thereof
CA2731164A1 (en)	2008-07-30	2010-02-04	Generics (Uk) Limited	Polymorphic form of rasagiline mesylate
EP2181980A1 (en)	2008-10-28	2010-05-05	Chemo Ibérica, S.A.	A process for the preparation of (R)-1-aminoindanes
DE102008064061A1 (de)	2008-12-19	2010-06-24	Ratiopharm Gmbh	Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline base formulation
DK2451771T3 (da)	2009-07-09	2014-09-08	Ratiopharm Gmbh	Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
US20110015274A1 (en)	2009-07-20	2011-01-20	Ester Masllorens Llinas	Form of an aminoindan mesylate derivative
AU2010274589A1 (en)	2009-07-23	2012-02-16	Alkem Laboratories Ltd.	Oral pharmaceutical composition of rasagiline and process for preparing thereof
EP2485722A1 (en) *	2009-10-09	2012-08-15	Teva Pharmaceutical Industries, Ltd.	Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
WO2011087791A1 (en) *	2009-12-22	2011-07-21	Teva Pharmaceutical Industries Ltd.	3-keto-n-propargyl-1-aminoindan

2009
- 2009-06-09 US US12/456,031 patent/US20100189788A1/en not_active Abandoned
- 2009-06-09 US US12/456,001 patent/US20100189791A1/en not_active Abandoned
- 2009-06-09 US US12/455,976 patent/US8080584B2/en not_active Expired - Fee Related
- 2009-06-09 US US12/456,029 patent/US20100189790A1/en not_active Abandoned
2010
- 2010-01-18 US US12/689,044 patent/US7855233B2/en not_active Expired - Fee Related
- 2010-01-21 EA EA201170962A patent/EA029262B1/ru not_active IP Right Cessation
- 2010-01-21 ES ES10733731.3T patent/ES2564317T3/es active Active
- 2010-01-21 JP JP2011547964A patent/JP5774495B2/ja not_active Expired - Fee Related
- 2010-01-21 CA CA2799515A patent/CA2799515A1/en not_active Abandoned
- 2010-01-21 CA CA2727899A patent/CA2727899C/en not_active Expired - Fee Related
- 2010-01-21 CN CN201080009551.4A patent/CN102333442B/zh not_active Expired - Fee Related
- 2010-01-21 AU AU2010206970A patent/AU2010206970B2/en not_active Ceased
- 2010-01-21 US US13/145,989 patent/US20120003310A1/en not_active Abandoned
- 2010-01-21 WO PCT/US2010/000174 patent/WO2010085354A1/en not_active Ceased
- 2010-01-21 CA CA2713292A patent/CA2713292C/en not_active Expired - Fee Related
- 2010-01-21 EP EP10733731.3A patent/EP2381767B1/en active Active
- 2010-01-22 DK DK10186379.3T patent/DK2308477T3/da active
- 2010-01-22 AT AT10186379T patent/ATE556703T1/de active
- 2010-01-22 PL PL10186379T patent/PL2308477T3/pl unknown
- 2010-01-22 PL PL10166534T patent/PL2246321T3/pl unknown
- 2010-01-22 AT AT10166534T patent/ATE518527T1/de active
- 2010-01-22 EP EP10186379A patent/EP2308477B1/en active Active
- 2010-01-22 SI SI201030050T patent/SI2308477T1/sl unknown
- 2010-01-22 RS RS20120337A patent/RS52421B/sr unknown
- 2010-01-22 PT PT10186379T patent/PT2308477E/pt unknown
- 2010-01-22 DE DE202010017129U patent/DE202010017129U1/de not_active Expired - Lifetime
- 2010-01-22 ES ES10186379T patent/ES2389889T3/es active Active
- 2010-01-22 EP EP10166534A patent/EP2246321B1/en active Active
- 2010-01-22 PT PT10166534T patent/PT2246321E/pt unknown
- 2010-01-22 SI SI201030008T patent/SI2246321T1/sl unknown
- 2010-01-22 ES ES10166534T patent/ES2370980T3/es active Active
- 2010-01-22 AT ATGM76/2011U patent/AT12508U1/de not_active IP Right Cessation
- 2010-01-22 RS RS20110487A patent/RS52033B/sr unknown
- 2010-01-22 DK DK10166534.7T patent/DK2246321T3/da active
- 2010-01-22 AR ARP100100139A patent/AR075148A1/es unknown
2011
- 2011-01-27 CZ CZ201123855U patent/CZ22819U1/cs not_active IP Right Cessation
- 2011-03-11 DK DKBA201100050U patent/DK201100050U4/da not_active IP Right Cessation
- 2011-07-20 IL IL214220A patent/IL214220A/en not_active IP Right Cessation
- 2011-10-13 HR HR20110745T patent/HRP20110745T1/hr unknown
- 2011-10-31 CY CY20111101033T patent/CY1112486T1/el unknown
- 2011-12-23 US US13/336,609 patent/US20120100189A1/en not_active Abandoned
2012
- 2012-06-29 US US13/538,715 patent/US20120263789A1/en not_active Abandoned
- 2012-07-31 CY CY20121100679T patent/CY1112954T1/el unknown
- 2012-08-02 HR HRP20120633AT patent/HRP20120633T1/hr unknown
2013
- 2013-12-23 US US14/139,212 patent/US20140186514A1/en not_active Abandoned
2014
- 2014-11-26 JP JP2014239283A patent/JP2015091813A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP2308477B1 (en)	2012-05-09
PT2308477E (pt)	2012-08-09
SI2246321T1 (sl)	2011-11-30
US20100190859A1 (en)	2010-07-29
HK1150308A1 (en)	2011-11-25
PL2308477T3 (pl)	2012-10-31
EP2381767A1 (en)	2011-11-02
CA2713292A1 (en)	2010-11-23
ES2370980T3 (es)	2011-12-26
AU2010206970B2 (en)	2016-05-05
IL214220A (en)	2016-03-31
CN102333442A (zh)	2012-01-25
CA2799515A1 (en)	2010-11-23
DE202010017129U1 (de)	2011-09-14
JP2012515775A (ja)	2012-07-12
CZ22819U1 (cs)	2011-10-24
RS52033B (sr)	2012-04-30
US20120263789A1 (en)	2012-10-18
SI2308477T1 (sl)	2012-09-28
US20120100189A1 (en)	2012-04-26
ES2389889T3 (es)	2012-11-02
US20100189790A1 (en)	2010-07-29
EP2381767A4 (en)	2014-12-24
US20100189787A1 (en)	2010-07-29
AU2010206970A1 (en)	2011-08-18
PT2246321E (pt)	2011-10-19
EA201170962A1 (ru)	2012-03-30
WO2010085354A1 (en)	2010-07-29
EP2246321A1 (en)	2010-11-03
CY1112486T1 (el)	2015-12-09
US8080584B2 (en)	2011-12-20
EA029262B1 (ru)	2018-02-28
CY1112954T1 (el)	2016-04-13
US20140186514A1 (en)	2014-07-03
CA2727899C (en)	2013-02-26
HRP20120633T1 (hr)	2012-09-30
US20100189788A1 (en)	2010-07-29
IL214220A0 (en)	2011-08-31
EP2381767B1 (en)	2016-01-20
ATE556703T1 (de)	2012-05-15
DK2246321T3 (da)	2011-11-21
EP2308477A1 (en)	2011-04-13
EP2246321B1 (en)	2011-08-03
RS52421B (sr)	2013-02-28
JP2015091813A (ja)	2015-05-14
US20120003310A1 (en)	2012-01-05
CA2727899A1 (en)	2010-11-23
ATE518527T1 (de)	2011-08-15
US7855233B2 (en)	2010-12-21
DK201100050U4 (da)	2014-10-24
AR075148A1 (es)	2011-03-09
ES2564317T3 (es)	2016-03-21
US20100189791A1 (en)	2010-07-29
CA2713292C (en)	2011-08-02
CN102333442B (zh)	2015-08-19
JP5774495B2 (ja)	2015-09-09
PL2246321T3 (pl)	2011-12-30
DK2308477T3 (da)	2012-08-13
HRP20110745T1 (hr)	2011-12-31
AT12508U1 (de)	2012-06-15

Publication	Publication Date	Title
DK2308477T3 (da)	2012-08-13	Rasagilinformulering med forsinket frisætning
BRPI1013622A2 (pt)	2016-10-25	cápsula liberadora
BR112012011733A2 (pt)	2019-09-24	formulações de comprimido de liberação imediata
EP2637696A4 (en)	2016-07-06	COMPOSITIONS WITH DELAYED RELEASE
BRPI1009465A2 (pt)	2015-08-18	Formulação
BRPI0912428A2 (pt)	2016-02-16	formulação farmacêutica sólida de liberação retardada
ZA201300105B (en)	2014-06-25	Creping release agents
GB0907003D0 (en)	2009-06-03	Formulation
EP2494966A4 (en)	2013-03-06	STABLE COMPOSITION OF RASAGILINE
CO6960544A2 (es)	2014-05-30	Preparación de liberación sostenida
EP2405777A4 (en)	2014-05-07	CLOTHING WITH QUICK REMOVAL
EP2661260A4 (en)	2014-05-14	BENZIMIDAZOLE FORMULATIONS WITH MODIFIED RELEASE
UY33127A (es)	2011-07-29	Formulación de liberación sostenida
GB201307109D0 (en)	2013-05-29	Release coating
HUE042857T2 (hu)	2019-07-29	Gyors hatóanyag-leadású készítmények
IT1399630B1 (it)	2013-04-26	Formulazioni alimentari a lento rilascio
IL218947A0 (en)	2012-07-31	Delayed release compositions
GB0911213D0 (en)	2009-08-12	Formulation
GB0907410D0 (en)	2009-06-10	Formulation
FIU20110119U0 (fi)	2011-03-31	Hidastetusti vapautuva rasagilinikoostumus
FI20100027A0 (fi)	2010-01-27	Laukaisin
FI8827U1 (fi)	2010-08-27	Pikakiinnike
IT1393211B1 (it)	2012-04-11	Dispositivo di innesto rapido
GB0911867D0 (en)	2009-08-19	Multiparticulate formulation
FI20100290A0 (fi)	2010-08-16	Mekaaninen voiman suuntaaja

Legal Events

Date	Code	Title	Description
2020-01-23	UUP	Utility model expired	Expiry date: 20200122